The resignation of the executive attracted heated discussion and looked at Hengrui's independent innovation drug base.

Recently, Hengrui Pharmaceuticals issued an announcement on the resignation of the company's executives, the content shows that hengrui four senior executives collectively resigned as deputy general manager, still working in the company.
news, triggered a heated discussion, the scope of the topic related to Heng Rui's innovation ability discussion.
undeniable, since 2018, the domestic market has gradually emerged a number of outstanding innovative pharmaceutical enterprises, including Baiji Shenzhou, Cinda Bio, Junshi Pharmaceuticals, etc., these enterprises have their own strengths, rise up to catch up, and gradually narrow the gap with Hengrui in the independent innovation drugs.
note, in May 2020, the British pharmaceutical information company IDEA Pharma released the 2020 Pharmaceutical Innovation Index and Pharmaceutical Invention Index ranking, Hengrui Pharmaceuticals for the first time on the list, ranked 13th and 15th, respectively, and is the only Chinese pharmaceutical company on the list, the innovation ability of the domestic leading enterprises is still recognized.
the opportunity of domestic domestic pharmaceutical enterprises to innovate drugs Independently Since 2018, the domestic drug market structure has gradually divided, the health insurance catalog dynamic adjustment, for therapeutic, high clinical value of innovative varieties to provide drug use scenarios;
in the context of the continuous optimization of the domestic drug innovation environment, the number of domestic declaration of innovative drugs, biological drugs showed accelerated growth, at the same time, the domestic also emerged a number of outstanding innovative pharmaceutical enterprises, they will focus on overseas, accelerate to the world, aimed at achieving global market sales.
as a leading domestic pharmaceutical companies, Hengrui Pharmaceuticals in the domestic market and foreign markets at both ends of the flowering, the domestic market has been approved a number of independent research and development products, and through the declaration of international clinical trials, independent research and development products to overseas markets.
domestic approved innovative drugs Since 2018, Hengrui has been approved for domestic marketing of four innovative drugs, including two class 1 chemical new drugs and 2 therapeutic biological products.
in particular, the PD-1 monoanti-Carelli strain has been approved for four indications in June 2019, and has been approved for Hodgkin's lymphoma, liver cancer, esophageal scale cancer, and non-small cell lung cancer.
these heavyweights will be a strong support for the company's future performance.

source: public data collation, enterprise annual report domestic declaration of the production of innovative drugs in addition to the approved listed innovative drugs, since 2018, Hengrui two innovative drugs sea-poppa ethanolamine tablets and fluoropyriparic capsules declared production, a class of new drug fluoropyri parly capsules as an innovative drug with obvious therapeutic advantages by the State Drug Administration Drug Review Center into the priority list of varieties, is expected to be approved for the year.

source: Open data collation to the FDA to declare clinical trials of innovative drugs as early as 2009, HengRui is trying to independent research and development of innovative drugs to the European and American markets, after more than ten years of continuous accumulation, HengRui to the FDA to declare clinical trials of innovative drugs have 9, indications covered malignant tumors, pain, psoriasis and diabetes.

source: public data collation, enterprise annual report According to incomplete statistics, up to now, 13 domestic pharmaceutical companies to the FDA to submit clinical applications for a total of 36 independent innovative drugs, Hengrui in the number of applications occupied an absolute advantage.
.